1American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, venti- lator-associated,and healthcare-associated pneumonia[ J]. Am J Re- spir Crit Care Med,2005,171 (4) :388-416.
2Masterton RG, Galloway A, French G, et al. Guidelines for the man- agement of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy [ J ]. J Antimicrob Chemother, 2008, 62 ( 1 ) : 5-34.
3Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries [ J ]. Am J Infect Control ,2008,36 (4) : S93-100.
5Tortes A, Ewig S, Lode H, et al. Defining, treating and preventing hos- pital acquired pneumonia : European perspective [ J ]. Intensive Care Med ,2009,35 ( 1 ) :9-29.
6Pugin J, Auckenthaler R, Mill N, et al. Diagnosis of ventilator-associ- ated pneumonia by bacteriologic analysis of bronchoscopic and non- bronchoscopic " blind" bronchoalveolar lavage fluid[ J]. Am Rev Re- spir Dis,1991,143(5) :1121-1129.
7Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infec- tion score for the identification and management of ventilator-associat- ed pneumonia. Intensive Care Med,2004,30 (5) :844-852.
8Croce MA, Swanson JM, Magnotti LJ, et al. The futility of the clinical pulmonary infection score in trauma patients [ J ]. J Trauma, 2006,60 (3) :523-528.
9Wunderink RG. Surrogate markers and mierobiologic end points [ J ]. Clin Infect Dis,2010,51 (S1) :S126-S130.
10Horonenko G, Hoyt JC, Robbins RA, et al. Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-as- sociated pneumonia:a preliminary report[ J]. Chest,2007,132 ( 1) : 58-63.
2Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med, 2002,165 : 867-903.
3Fagon JY, Chastre J, Hance A J, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med, 1993,94:281-288.
4Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of pneumonia in a large US database. Chest, 2002,122 : 2115-2121.
5Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med, 2005, 33 : 2184-2193.
6Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest, 1997, 111: 676-685.
7Horan TC, Gaynes RP. Surveillance of nosocomial infections. In : Hospital Epidemiology and Infection Control, 3rd ed. Mayhall CG, editor. Philadelphia: Lippincott Williams & Wilkins, 2004: 1659-1702.
8Clinical and Laboratory Standards Institute. Performance standards for antimicrohial susceptibility testing; twentieth informational supplement. Vol. 30. Wayne : Pennsylvania( USA. ), 2010 : M100- S19.
9Pach6n-Ib6fiez ME, Jim6nez-Mejias ME, Pichardo C, et al. Activity of tigecycline ( GAR-936 ) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother, 2004,48:4479-4481.
10American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator-associated, and pneumonia. Am J Respir Crit Care Med, 2005,171:388-416.